Nach Empfehlung der Deutschen Akademie für Kinder- und Jugendgesundheit e. V. und des Ministeriums für Inneres und Kommunales des Landes NRW
MMWR. Recommendations and Reports:
December 16, 2005 / 54(RR15);49-55
Pour l'achat de tests de diagnostic rapide du paludisme (TDR), plusieurs critères sont recommandés pour garantir la qualité et l'efficacité des tests. Ces critères se basent notamment sur la performance des tests, leur stabilité, leur facilité d'utilisation, leur coût et leur conformité aux... standards de l'Organisation Mondiale de la Santé (OMS)
more
MOBILISIERUNG INLÄNDISCHER ÖFFENTLICHER RESSOURCEN FÜR GESUNDHEIT
Global COVID-19 Clinical Platform: Case Record Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
Accessed 18 June 2018 | Last updated 1-Jun.-2018 (data as of 25-May-2018) | Next overall update Mid-July 2018
Dispatches
DOI: http://dx.doi.org/10.3201/eid2203.151607
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 3, March 2016
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
The WHO Cholera Rapid Diagnostic Test (RDT) Target Product Profile outlines the key requirements for developing improved cholera RDTs. It highlights the need for fast, accurate, and easy-to-use tests for early outbreak detection in resource-limited settings. The document sets desired and acceptable ...performance criteria, including high sensitivity and specificity, rapid results (under 15 minutes), and usability by non-laboratory personnel. The tests should be affordable, stable in extreme conditions, and require minimal training. The goal is to enhance cholera surveillance and outbreak response, ensuring quick containment and improved public health outcomes.
more
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0214-064-00
WHO PQDx PR
April/2016, version 3.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
Scientific brief
8 April 2020
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages